Trump Order Alters Medicare Drug Price Negotiations
Tap title to read story
President Trump issued an executive order partially overturning the Inflation Reduction Act's Medicare drug price negotiation provision. The order targets the disparity between negotiation timelines for small-molecule and biologic drugs, addressing the pharmaceutical industry's concerns about the 'pill penalty' hindering innovation. While this could increase Medicare spending and drug prices, it's expected to benefit some drugmakers significantly. However, the order also includes proposals opposed by the industry, such as increased drug imports from Canada, leaving the overall impact uncertain.
President Trump issued an executive order partially overturning the Inflation Reduction Act's Medicare drug price negotiation provision. The order targets the disparity between negotiation timelines for small-molecule and biologic drugs, addressing the pharmaceutical industry's concerns about the 'pill penalty' hindering innovation. While this could increase Medicare spending and drug prices, it's expected to benefit some drugmakers significantly. However, the order also includes proposals opposed by the industry, such as increased drug imports from Canada, leaving the overall impact uncertain.
More context
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.
